ÂÜÀòÂÒÂ×

Brian Liu, MD, is a Principal at Longitude Capital. Dr. Liu is a board observer at Quanta Therapeutics and Rivus Pharmaceuticals. He previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche), Talaris Therapeutics (TALS), and Vera Therapeutics (VERA). Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey & Company. Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from Johns Hopkins University.